Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Flerie ABFRA:1NP1 37 EBIT per Share is €-0.76 as of Jun. 2026. GuruFocus rates FRA:1NP1 with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 1,173 Biotechnology companies, Flerie AB ranks better than 95.31% on this metric.
Flerie AB's EBIT per Share for the
three
months ended in Jun. 2026 was €-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.76.
During the past 3 years, the average EBIT per Share Growth Rate was 74.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 59.70% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 32.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Flerie AB's EBIT per Share or its related term are showing as below:
FRA:1NP1'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -79.1 Med: 14.2 Max: 74.8
Current: 74.8
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Flerie AB was 74.80% per year. The lowest was -79.10% per year. And the median was 14.20% per year.
FRA:1NP1's 3-Year EBIT Growth Rate is ranked better than 95.31% of 1173
companies
in the Biotechnology industry
Industry Median: 15.5
vs FRA:1NP1: 74.80
Flerie AB's EBIT for the
three
months ended in Jun. 2026 was €-0.89 Mil.
Flerie AB (FRA:1NP1) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Flerie AB EBIT per Share Related Terms
Flerie AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Flerie AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flerie AB (FRA:1NP1) has a EBIT per Share of €-0.76 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Flerie AB and its competitors. According to the industry distribution chart, Flerie AB ranks #55 out of 1173 companies in the Biotechnology industry, placing it in the top 4.7%.
Is Flerie AB's EBIT per Share too high?
Flerie AB's current EBIT per Share is €-0.76. Based on the distribution chart, Flerie AB ranks #55 out of 1173 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Flerie AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Flerie AB ranks #55 out of 1173 companies for EBIT per Share. This places Flerie AB in the top 5% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Flerie AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Flerie AB's current EBIT per Share is €-0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (FRA:1NP1) has a current EBIT per Share of €-0.76. The current EBIT per Share is €-0.76. Flerie AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Flerie AB (FRA:1NP1), the current EBIT per Share is €-0.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
37GF Score
Get the complete analysis for FRA:1NP1
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1NP1 has been successfully added to your 
